VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BGMS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
BGMSBio Green Med Solution, Inc.
$0.72$2M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksBGMSFinancials

Bio Green Med Solution, Inc. (BGMS) Financials

21Y historyFree accessUpdated daily

The company's shift toward industrial operations has stabilized gross margins at 18.3% in 2026Q1, though this is insufficient to overcome an operating margin of -31.6%.

BGMS Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05
Sales/Revenue1.52M747K43K420K0000150K0843K1.94M1.73M1.08M69K699K686K911K877K129K387K356K
Revenue Growth %10792.86%1637.21%-89.76%-----100%--100%-56.64%12.11%59.96%1471.01%-90.13%1.9%-24.7%3.88%579.85%-66.67%8.71%-
Cost of Goods Sold1.25M609K0032K43K20K4.66M4.33M4.24M9.48M12.38M18.28M00360K875K1.21M2.29M1.12M1.12M1.32M
COGS % of Revenue-81.53%------2884.67%-1124.2%636.93%1054.04%--51.5%127.55%133.15%261.23%871.32%290.44%371.35%
Gross Profit279K138K43K420K-32K-43K-20K-4.66M-4.18M-4.24M-8.63M-10.44M-16.54M00339K-189K-302K-1.41M-995K-737K-966K
Gross Margin %18.3%18.47%100%100%-----2784.67%--1024.2%-536.93%-954.04%--48.5%-27.55%-33.15%-161.23%-771.32%-190.44%-271.35%
Gross Profit Growth %-220.93%-89.76%1412.5%25.58%-115%99.57%-11.52%1.42%50.93%17.28%36.9%---100%279.37%37.42%78.64%-42.11%-35.01%23.71%-
Operating Expenses3.92M8.56M12.05M25.87M27.66M22.39M10.62M5.02M5.37M5.25M5.52M5.73M5.89M18.99M15.11M16.73M16.08M17.64M32.36M29.99M32.4M19.81M
OpEx % of Revenue-1146.59%28016.28%6160.24%----3580.67%-654.33%294.86%339.91%1751.66%21901.45%2392.99%2343.59%1935.89%3689.97%23246.51%8372.09%5564.33%
Selling, General & Admin3.89M7.72M5.39M6.72M7.38M7.46M5.88M5.02M5.37M5.25M5.52M5.73M5.89M7.71M8.52M7.52M9.66M7.87M13.49M10.42M11.2M3.97M
SG&A % of Revenue-1033.07%12539.53%1599.52%----3580.67%-654.33%294.86%339.91%711.35%12347.83%1075.97%1408.6%863.89%1538.43%8076.74%2892.76%1114.61%
Research & Development24K848K6.66M19.16M20.27M14.93M4.74M4.66M4.33M4.24M9.48M12.38M18.28M11.28M6.59M9.21M6.41M9.77M18.87M19.57M21.2M15.84M
R&D % of Revenue-113.52%15476.74%4560.71%----2884.67%-1124.2%636.93%1054.04%1040.31%9553.62%1317.02%934.99%1072.01%2151.54%15169.77%5479.33%4449.72%
Other Operating Expenses0000000-4.66M-4.33M-4.24M-9.48M-12.38M-18.28M000000000
Operating Income-3.64M-8.43M-12M-25.45M-27.66M-22.39M-10.64M-9.68M-9.55M-9.49M-14.15M-16.17M-22.44M-17.97M-15.1M-16.39M-16.27M-17.94M-33.77M-30.98M-33.14M-20.77M
Operating Margin %-238.49%-1128.11%-27916.28%-6060.24%-----6365.33%--1678.53%-831.79%-1293.94%-1658.12%-21888.41%-2344.49%-2371.14%-1969.04%-3851.2%-24017.83%-8562.53%-5835.67%
Operating Income Growth %-29.8%52.84%7.97%-23.52%-110.5%-9.85%-1.4%-0.6%32.93%12.49%27.93%-24.83%-19.01%7.84%-0.75%9.32%46.89%-9.01%6.5%-59.5%-
EBITDA-3.63M-8.42M-12M-25.42M-27.62M-22.35M-10.62M-9.66M-9.52M-9.46M-14.02M-15.96M-22.26M-17.9M-15.04M-16.15M-15.81M-17.27M-31.91M-29.86M-32.01M-19.45M
EBITDA Margin %-238%-1127.44%-27902.33%-6052.86%-----6346%--1662.75%-820.99%-1283.91%-1651.66%-21801.45%-2310.01%-2304.52%-1895.72%-3638.88%-23146.51%-8272.09%-5464.33%
EBITDA Growth %71.38%29.8%52.8%7.97%-23.62%-110.49%-9.87%-1.5%-0.63%32.52%12.17%28.31%-24.35%-19.02%6.84%-2.14%8.46%45.88%-6.88%6.73%-64.57%-
D&A (Non-Cash Add-back)7.5K5K6K31K32K43K20K20K29K32K133K210K174K70K60K241K457K668K1.86M1.12M1.12M1.32M
EBIT-3.64M-8.43M-12M-25.45M-27.66M-22.39M-9.68M-9.68M-9.55M-9.49M-14.15M-16.17M-22.44M-11.88M-15.11M-15.81M-16.63M-20.34M-41.82M-25.87M-31.25M-19.89M
Net Interest Income65K62K12K266K210K16K42K224K331K118K37K9K6K13K22K45K-6K-75K1.06M3.33M2.07M827K
Interest Income65K62K12K266K210K16K42K224K331K118K37K9K6K13K22K45K37K102K1.38M3.55M2.33M887K
Interest Expense000000000000000043K177K318K223K254K60K
Other Income/Expense560K5.44M10K-98K1.74M204K955K556K923K1.03M376K-316K-212K6.09M-4K580K-412K-2.58M-8.36M4.89M1.63M827K
Pretax Income-3.08M-2.99M-11.99M-25.55M-25.91M-22.18M-9.68M-9.13M-8.63M-8.46M-13.77M-16.49M-22.65M-11.88M-15.11M-15.81M-16.68M-20.52M-42.13M-26.09M-31.5M-19.95M
Pretax Margin %-201.77%-400.4%-27893.02%-6083.57%-----5750%--1633.93%-848.05%-1306.17%-1095.94%-21894.2%-2261.52%-2431.2%-2252.25%-4804.45%-20227.91%-8140.31%-5603.37%
Income Tax37K7K-782K-3M-4.72M-3.73M-1.24M1.3M1.34M993K1.98M2.14M3.24M-1.67M-1.35M-565K-657K-948K-1.75M-2.04M-2.25M-1.9M
Effective Tax Rate %-1.2%-0.23%6.52%11.73%18.2%16.8%12.77%-14.2%-15.5%-11.73%-14.4%-13%-14.32%14.06%8.94%3.57%3.94%4.62%4.15%7.82%7.13%9.52%
Net Income-3.11M-3M-11.21M-22.55M-21.2M-18.46M-8.45M-7.83M-7.29M-7.47M-11.79M-14.34M-19.39M-10.15M-13.19M-15.24M-16.02M-19.57M-40.39M-24.05M-29.26M-18.05M
Net Margin %-204.2%-401.34%-26074.42%-5370.24%-----4858.67%--1398.7%-737.76%-1118.05%-936.62%-19110.14%-2180.69%-2335.42%-2148.19%-4605.02%-18645.74%-7560.21%-5069.66%
Net Income Growth %62.69%73.26%50.29%-6.4%-14.85%-118.56%-7.85%-7.44%2.44%36.65%17.79%26.02%-90.95%23%13.49%4.86%18.13%51.54%-67.9%17.79%-62.11%-
Net Income (Continuing)-3.11M-3M-11.21M-22.55M-21.2M-18.46M-8.45M-7.83M-7.29M-7.47M-11.79M-14.34M-19.41M-10.21M-13.76M-15.24M-16.02M-19.57M-40.39M-24.05M-29.26M-18.05M
Discontinued Operations00000000000019K57K570K0000000
Minority Interest0000000000000000000000
EPS (Diluted)-0.57-6.45-501.60-6420.00-6840.00-7704.00-12306.00-35426.00-44584.00-140400.00-252000.00-388800.00-768960.00-999999.00-999999.00-999999.00-999999.00-999999.00-999999.00-999999.00-999999.00-999999.00
EPS Growth %99.4%98.71%92.19%6.14%11.21%37.4%65.26%20.54%68.25%44.29%35.19%49.44%30.47%23.81%25%38.46%40.91%55.56%-63.64%49.58%84.11%-
EPS (Basic)--6.45-501.60-6420.00-6840.00-7704.00-12306.00-35426.00-44584.00-140400.00-252000.00-388800.00-768960.00-999999.00-999999.00-999999.00-999999.00-999999.00-999999.00-999999.00-999999.00-999999.00
Diluted Shares Outstanding5.46M2.19M22.31K3.54K3.13K2.48K1.01K22716810648382518108643300
Basic Shares Outstanding5.46M2.19M22.31K3.54K3.13K2.48K1.01K22716810648382518108643300
Dividend Payout Ratio----------------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Unsustainable cash burn rate

Inorganic Revenue Shift Masks Volatility

According to the provided financial data, BGMS reported a revenue of $778,000 in 2026Q1, representing a significant departure from the near-zero revenue periods seen in 2025, which suggests the company has successfully transitioned toward consolidating the Fitters Sdn. Bhd. industrial fire protection business into its core operations.

The dramatic revenue jump appears to be driven by the acquisition of the Malaysian fire safety business rather than organic growth within the biopharmaceutical segment. Investors should monitor whether this project-based revenue can maintain consistency, as the reliance on construction-linked contracts may introduce cyclical volatility that is not yet fully reflected in the short-term data.

Industrial Transition Compresses Gross Margins

As reported in the income statement, the company's gross margin has stabilized at approximately 18.3% in 2026Q1, a sharp decline from the historical highs observed when the firm was primarily focused on speculative biopharmaceutical research activities that lacked meaningful commercial scale or consistent cost of goods sold.

The current margin profile reflects the transition to a labor-intensive and material-heavy industrial service model. This structural shift suggests that the company is unlikely to achieve the high-margin profile typical of the healthcare sector unless the biopharmaceutical pipeline reaches a commercialization stage that provides higher-margin revenue streams.

Operating Leverage Remains Severely Constrained

Based on the most recent quarterly filings, BGMS continues to struggle with extreme operating leverage, as evidenced by an operating margin of -31.6% in 2026Q1, which indicates that the current revenue base is insufficient to cover the substantial corporate overhead required to maintain a dual-industry public entity.

The persistent gap between gross profit and operating expenses suggests that the company is burdened by excessive administrative costs relative to its current scale. Without a significant increase in revenue or a drastic reduction in corporate overhead, the company may continue to face difficulty in achieving operational break-even.

Diworsification Risks and Capital Exhaustion

Financial statements indicate that the company's strategy of operating in two unrelated industries—biopharma and fire safety—has resulted in a -1128% operating margin over the trailing twelve months, raising concerns about whether management can effectively allocate capital across such disparate business units without further diluting shareholder value.

Short-sellers would likely focus on the high probability of future equity dilution, as the current cash burn rate appears unsustainable relative to the company's $3.5 million cash position. The lack of operational synergy between the Malaysian fire protection business and the US-based biopharma arm warrants further investigation into whether this structure is designed for long-term value creation or merely survival.

BGMS — Frequently Asked Questions

Quick answers to the most common questions about buying BGMS stock.

What was Bio Green Med Solution, Inc.'s (BGMS) revenue in 2025?

For fiscal year 2025, Bio Green Med Solution, Inc. (BGMS) reported total revenue of $0.7M. This represents a 109.8% increase compared to $0.4M in 2005.

Is Bio Green Med Solution, Inc. (BGMS) profitable?

Bio Green Med Solution, Inc. (BGMS) reported a net loss of $3.0M for the fiscal year ending 2025.

What is Bio Green Med Solution, Inc.'s operating profit margin?

Bio Green Med Solution, Inc. (BGMS) reported an operating income of $-8.4M, resulting in an operating profit margin of -1128.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Bio Green Med Solution, Inc.'s gross profit and gross margin?

Bio Green Med Solution, Inc. (BGMS) generated $0.1M in gross profit for the year, representing a gross profit margin of 18.5%. This demonstrates the company's core pricing power and production efficiency.